MedPath

Levosimendan

Generic Name
Levosimendan
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H12N6O
CAS Number
141505-33-1
Unique Ingredient Identifier
C6T4514L4E
Background

Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication

For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions
Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
Associated Therapies
Positive cardiac inotropic effect, Intravenous inotropic therapy

Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.

Phase 4
Completed
Conditions
Heart Failure
First Posted Date
2005-09-22
Last Posted Date
2017-03-20
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
60
Registration Number
NCT00219388
Locations
🇸🇪

Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden

Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery

Phase 3
Terminated
Conditions
Heart Failure
First Posted Date
2005-09-14
Last Posted Date
2013-11-15
Lead Sponsor
Emory University
Target Recruit Count
1
Registration Number
NCT00166127
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

Levosimendan in High Risk Heart Valve Surgery

Phase 4
Completed
Conditions
Heart Failure
Interventions
Drug: placebo
Drug: levosimendan
First Posted Date
2005-09-12
Last Posted Date
2009-01-21
Lead Sponsor
Kuopio University Hospital
Target Recruit Count
200
Registration Number
NCT00154115
Locations
🇫🇮

Kuopio University Hospital, Kuopio, Finland

Peroral Levosimendan in Chronic Heart Failure

Phase 2
Completed
Conditions
Chronic Heart Failure
Heart Diseases
First Posted Date
2005-08-16
Last Posted Date
2007-02-21
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
300
Registration Number
NCT00130884
Locations
🇫🇮

Helsinki University Central Hospital, Helsinki, Finland

Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

Phase 2
Completed
Conditions
Coronary Heart Disease
First Posted Date
2005-08-16
Last Posted Date
2007-02-21
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
60
Registration Number
NCT00130871
Locations
🇫🇮

Helsinki University Central Hospital, Helsinki, Finland

🇫🇮

Turku University Central Hospital, Turku, Finland

Levosimendan Versus Dobutamine in Shock Patients

Phase 2
Conditions
Cardiogenic Shock
Septic Shock
First Posted Date
2004-10-07
Last Posted Date
2005-06-24
Lead Sponsor
Wentworth Area Health Services
Target Recruit Count
40
Registration Number
NCT00093301
Locations
🇦🇺

Intensive Care Unit, Nepean Hospital, Penrith, New South Wales, Australia

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Phase 3
Completed
Conditions
Heart Failure, Congestive
First Posted Date
2002-11-04
Last Posted Date
2006-12-15
Lead Sponsor
Abbott
Target Recruit Count
600
Registration Number
NCT00048425
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

and more 163 locations
© Copyright 2025. All Rights Reserved by MedPath